Education
About Us
Working with TipRanks
Follow Us
Daxor Corp (DXR)
NASDAQ:DXR
DXR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.55 - $11.48
Previous CloseN/A
Volume734.00
Average Volume (3M)55.41K
Market Cap
$35.03M
Enterprise Value$48.82M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)30.3
Beta0.41
Next Earnings
Feb 26, 2026EPS EstimateN/A
Last Dividend Ex-Date
Jan 05, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding4,962,245
10 Day Avg. Volume7,106
30 Day Avg. Volume55,405
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue63.64
Enterprise Value/Gross Profit70.50
Enterprise Value/Ebitda-50.72
Forecast
1Y Price Target
$22.00Price Target Upside98.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported strong revenue growth of +117% in its blood volume business across leading medical centers in the U.S.
Regulatory ApprovalThe next-gen blood volume analyzer (BVA) from Daxor received FDA 510(k) clearance, which is expected to accelerate its adoption.
Bears Say
Investment ClassificationDaxor’s engagement with the SEC to transition from its current investment company classification to an operating company should improve financial transparency, attract a broader investor base, and potentially lead to increased trading volume.
Regulatory StrategyThe decision to pivot to a single 510(k) submission, rather than a dual CLIA waiver approach, is a prudent regulatory strategy that reduces data burden and accelerates the approval timeline.
Daxor News
DXR FAQ
What was Daxor Corp’s price range in the past 12 months?
Daxor Corp lowest stock price was $6.55 and its highest was $11.48 in the past 12 months.
What is Daxor Corp’s market cap?
Daxor Corp’s market cap is $35.03M.
When is Daxor Corp’s upcoming earnings report date?
Daxor Corp’s upcoming earnings report date is Feb 26, 2026 which is in 172 days.
How were Daxor Corp’s earnings last quarter?
Daxor Corp released its earnings results on Aug 21, 2025. The company reported -$0.074 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.074.
Is Daxor Corp overvalued?
According to Wall Street analysts Daxor Corp’s price is currently Undervalued.
Does Daxor Corp pay dividends?
Daxor Corp pays a Monthly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Daxor Corp dividends here
What is Daxor Corp’s EPS estimate?
Daxor Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daxor Corp have?
Daxor Corp has 4,962,245 shares outstanding.
What happened to Daxor Corp’s price movement after its last earnings report?
Daxor Corp reported an EPS of -$0.074 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.498%.
Which hedge fund is a major shareholder of Daxor Corp?
Currently, no hedge funds are holding shares in DXR
Daxor Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (98.92% Upside)
$22.00 (98.92% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.66%
12-Months-Change
Fundamentals
Return on Equity
5.26%
Trailing 12-Months
Asset Growth
4.44%
Trailing 12-Months
Company Description
Daxor Corp
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
DXR Stock 12 Month Forecast
Average Price Target
$22.00
▲(98.92% Upside)
Technical Analysis
Merit Medical Systems
―
Pro-Dex
―
Milestone Scientific
―
Femasys
―
Meihua International Medical Technologies Co., Ltd.
―
Ownership Overview
5.44% Insiders
1.00% Mutual Funds
0.32% Other Institutional Investors
92.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---